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Abstract To facilitate smoking genetics research we determined whether a screen of
mutagenized zebrafish for nicotine preference could predict loci affecting smoking behaviour. From
30 screened F3 sibling groups, where each was derived from an individual ethyl-nitrosurea
mutagenized F0 fish, two showed increased or decreased nicotine preference. Out of 25
inactivating mutations carried by the F3 fish, one in the slit3 gene segregated with increased
nicotine preference in heterozygous individuals. Focussed SNP analysis of the human SLIT3 locus in
cohorts from UK (n=863) and Finland (n=1715) identified two variants associated with cigarette
consumption and likelihood of cessation. Characterisation of slit3 mutant larvae and adult fish
revealed decreased sensitivity to the dopaminergic and serotonergic antagonist amisulpride,
known to affect startle reflex that is correlated with addiction in humans, and increased htr1aa
mRNA expression in mutant larvae. No effect on neuronal pathfinding was detected. These
findings reveal a role for SLIT3 in development of pathways affecting responses to nicotine in
zebrafish and smoking in humans.
Introduction
Tobacco smoking is the leading preventable cause of death worldwide placing a heavy social and
financial burden on society (World Health Organization, 2017; National Center for Chronic Dis-
ease Prevention and Health Promotion (US) Office on Smoking and Health, 2014; Xu et al.,
2015). It is well established that aspects of smoking behaviour have a strong genetic component
(Munafo` et al., 2004; Batra et al., 2003; Liu et al., 2019; Erzurumluoglu et al., 2019). However,
identifying causal genetic factors and exploring the mechanisms by which they act is challenging in
human studies: the field has been characterized by small effect sizes and lack of replication such that
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there are remarkably few genes and loci that can be confidently linked to smoking. The strongest
evidence for causal effects is for functional variants in CHRNA5 (Chen et al., 2015) and CYP2A6
(Munafo` et al., 2004) affecting amount smoked and nicotine metabolism, respectively. Recent large
studies have identified numerous new association loci, but their significance is yet to be biologically
characterised (Liu et al., 2019; Erzurumluoglu et al., 2019).
As approaches to identify genetic risk are difficult in humans, research has been facilitated by
studies in animal models, with a focus on genomic analysis of inbred and selectively-bred, naturally
occurring genetic strains (Crabbe, 2008). This type of study produces quantitative trait loci (QTL)
maps of multiple loci, each with a small impact on the phenotype. However, as with human studies,
it is inherently difficult to identify relevant genes from QTL maps, as the overall phenotype cannot
be predicted by individual genotypes. Mutagenesis studies in animal model systems can overcome
these limitations: e.g. N-ethyl-N-nitrosourea (ENU) mutagenesis introduces thousands of point muta-
tions into the genome with the potential to generate much stronger phenotypes than those occur-
ring in a natural population thereby facilitating identification of causal mutations. Examination of
phenotypic variation in ENU mutagenized model species could be applied to identify novel, naturally
occurring variants influencing human addictive behaviour by identifying key genes and pathways
affecting conserved behavioural phenotypes.
Drug-induced reinforcement of behaviour, that reflects the hedonic value of drugs of abuse
including nicotine, is highly conserved in both mammalian and non-mammalian species (Parker and
Brennan, 2012; Engleman et al., 2016; Shipley et al., 2017; Berridge and Kringelbach, 2008).
Conditioned place preference (CPP), where drug exposure is paired with specific environmental
cues, is commonly used as a measure of drug-induced reward or reinforcement (Tzschentke, 1998).
ENU Mutagenesis screens for cocaine or amphetamine-induced CPP have been undertaken in zebra-
fish (Darland and Dowling, 2001; Ninkovic et al., 2006), however, despite successful isolation of
lines with altered reinforcement responses to these drugs, the causal mutations have not been iden-
tified and the predictive validity of these screens for human behaviour has not been established. Lar-
val locomotor response to nicotine has also been used to explore nicotine response genetics
(Petzold et al., 2009) but the relevance of larval locomotion to addiction is somewhat less clear.
Here, we conducted a forward genetic screen of ENU-mutagenized zebrafish for nicotine-induced
CPP. Zebrafish express homologues of all 16 members of the nicotinic acetylcholine receptor family
present in mammals (Zirger et al., 2003; Ackerman et al., 2009; Pedersen et al., 2019) with similar
binding characteristics (Papke et al., 2012; Ponzoni et al., 2014). However, as a result of a local
gene duplication event in the ray fish lineage and a teleost genome tetraploidation event, zebrafish
have duplicate copies of nicotinic receptor a2, a4, a7, a9, a10, b1, b3 and b5. In addition, zebrafish
have additional receptors (a8 and a11) that have been lost in humans (Pedersen et al., 2019).
Zebrafish show robust CPP to nicotine (Ponzoni et al., 2014; Kily et al., 2008; Brock et al., 2017;
Kedikian et al., 2013). Nicotinic receptor partial agonists, that modulate striatal dopamine release
in response to nicotine in mammalian systems, also inhibit nicotine-induced CPP in zebrafish
(Ponzoni et al., 2014). Further, on prolonged exposure to nicotine or ethanol, adult zebrafish show
conserved adaptive changes in gene expression and develop dependence-related behaviours, such
as persistent drug seeking despite adverse stimuli or reinstatement of drug seeking following peri-
ods of abstinence (Kily et al., 2008; Kedikian et al., 2013). These data demonstrate the existence
of a conserved nicotine-responsive reward pathway and support the suitability of zebrafish to exam-
ine the genetic and molecular mechanisms underlying behavioural responses to nicotine.
To evaluate the use of a behavioural CPP screen in zebrafish to predict loci affecting human
smoking behaviour we initially assessed 1) the ability of varenicline and bupropion, pharmacological
agents used to treat human nicotine addiction, to reduce zebrafish nicotine-induced place prefer-
ence and 2) the heritability of nicotine responses in ENU-mutagenized fish. We then screened 30
F3 families of ENU-mutagenized fish to identify families with increased/decreased CPP for nicotine.
For two families with altered CPP response, the phenotype was confirmed following independent
replication with a larger number of fish. Exome sequence information was used to generate a list of
coding, loss of function candidate mutations affecting the phenotype. One family with a mutation
co-segregating with increased nicotine CPP was selected for further study. Firstly, the effect of the
identified gene on nicotine-induced CPP was confirmed using an independent line carrying a similar
predicted loss of function mutation in the same gene. We then characterized the mutation using
gene expression analysis, immunohistochemical analysis of neuronal pathways and behavioural
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responses to acoustic startle; a response known to be modulated by serotonergic and dopaminergic
signalling and, in humans, associated with vulnerability to addiction (Loeber et al., 2007;
Vrana et al., 2015; Kumari and Gray, 1999). Finally, we used focused single nucleotide polymor-
phism (SNP) analysis of human cohorts to assess the predictive validity of findings in fish for human
smoking behaviour.
In agreement with previous studies zebrafish showed a robust CPP to nicotine. Nicotine-induced
CPP was abolished by varenicline and bupropion and found to be heritable in fish. The screening of
ENU mutagenized families of zebrafish identified mutations in the slit3 gene influencing sensitivity to
rewarding effects of nicotine. Slit3 mutant larvae and adult fish showed reduced behavioural sensitiv-
ity to amisulpride and larvae showed increased ht1raa receptor expression. No effect on neuronal
pathfinding was detected. Analysis of the SLIT3 locus in two independent human cohorts identified
two genetic markers associated with level of cigarette consumption and likelihood of cessation. This
proof of principle study demonstrates that screening of zebrafish is able to predict loci affecting
complex human behavioural phenotypes and suggests a role for SLIT3 signalling in the development
of dopaminergic and serotonergic pathways affecting behaviours associated with nicotine sensitivity.
Results
Nicotine CPP in zebrafish is inhibited by varenicline and buproprion
The hedonic value of drugs of abuse, that gives rise to reinforced behaviour, is commonly assessed
using either self-administration protocols or CPP. The ability of compounds used as therapeutics in
humans to prevent rodent nicotine self-administration is used to support the translational relevance
of nicotine-self administration in that model (Hall et al., 2015; O’Connor et al., 2010; Le Foll et al.,
2012). As our aim was to use nicotine-CPP to predict genes affecting smoking behaviour, we
assessed the ability of the nicotine therapeutics varenicline and bupropion to inhibit nicotine induced
CPP in zebrafish. As seen previously (Kily et al., 2008; Kedikian et al., 2013; Brennan et al., 2011),
10 mM nicotine induced a robust 15–20% change in place preference. Consistent with previous
results (Ponzoni et al., 2014), pre-incubation in varenicline or bupropion dose-dependently inhibited
the nicotine CPP response (Figure 1).
Nicotine CPP is heritable in zebrafish
We selected a nicotine concentration predicted to induce a minimal detectable CPP in wild types (5
mM) (Kily et al., 2008; Brock et al., 2017), to enable us to detect both increased and decreased
response to nicotine in mutants. To ensure that this strategy could detect genetic factors affecting
response to nicotine, we assessed the heritability of the CPP response in ENU mutagenized fish
using a selective breeding approach over three generations. Figure 2A shows our assessment strat-
egy where fish showing the highest and lowest CPP response are selected for further breeding. In
the first generation, the CPP change score phenotype was normally distributed (Shapiro-Wilks
p=0.83) and there was a mean CPP change score of 0.11 to the drug paired side. CPP change scores
ranged from -0.4 to 0.6.
An increasing difference in nicotine preference between offspring of fish from the upper vs lower
extremes of the distribution (Shift of Cohen’s d = 0.89 in Second generation CPP to d = 1.64 in Third
generation CPP) indicates that nicotine CPP behaviour is heritable in zebrafish (Figure 2B), and that
our CPP strategy is able to identify heritable differences in both extremes of the distribution. Pheno-
types in the second and third generation screen may result from selecting for multiple co-segregat-
ing mutations that strengthened the phenotypes, or from selecting against other contrary mutations
that weaken effects.
Identification of slit3 mutations affecting nicotine place preference in
zebrafish
Out of 30 families screened, individuals from nine families were in the top 5% of the change in pref-
erence distribution, and individuals from five families in the bottom 5%. To identify candidate muta-
tions affecting nicotine preference in fish, we focussed on families where all individuals included in
the screen clustered at one or other extreme of the distribution curve. Two families (called AJBQM1
and AJBQM2 after the researcher who conducted the screen), which clustered at the top (AJBQM1)
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Figure 1. 10 mM nicotine induced place preference in zebrafish is sensitive to inhibition by therapeutics effective in
humans. (A) Varenicline (nicotine partial agonist) and (B) Bupropion (norepinephrine and dopamine reuptake
inhibitor with nicotine antagonist properties when metabolised). Bars represent mean and error bars represent
+ SEM. Asterisk (*) represents significance at p<0.05.
The online version of this article includes the following source data for figure 1:
Source data 1. Inhibition of nicotine CPP by varenicline and bupropion.
Figure 2. Nicotine CPP is heritable. (A) Breeding and selection to assess heritability of nicotine-induced place
preference in ENU-mutagenized zebrafish. To test whether nicotine preference is heritable, fish in the upper (blue
circle) and lower (red circle) 10% of the change in preference distribution curve were inbred and screened for CPP
(Second generation CPP assay). A similar approach was used for the third generation CPP assay. (B) CPP for
nicotine is heritable. Mean preference change is increasingly distinct for the second and third generation CPP
analysis. Plot represents mean and ± SEM. First generation (corresponding to the F3 families used for the screen)
(n = 120): mean = 0.11; SD = 0.17. Second generation: Offspring of fish from upper 10% of the first generation
screen (n = 92): mean = 0.17; SD = 0.14. Offspring of fish from lower 10% of the first generation screen (n = 64):
mean = 0.08; SD = 0.15. Third generation. Offspring of fish from upper 10% of the second generation screen
(n = 69): mean = 0.21; SD = 0.10. Offspring of fish from lower 10% of the second generation screen (n = 67):
mean = 0.01; SD = 0.09.
The online version of this article includes the following source data for figure 2:
Source data 1. Nicotine CPP over three generations.
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and bottom (AJBQM2) of the nicotine preference distribution, were selected for further study. We
first assessed nicotine CPP in the remaining siblings not initially included in the screen. As shown in
Figure 3, the phenotypes were conserved when remaining siblings were assessed. Exome sequenc-
ing of fish (Kettleborough et al., 2013) used to generate AJBQM1 and AJBQM2 identified 25 non-
sense and essential splice site mutations. We genotyped fish at these 25 loci and determined the co-
segregation with nicotine preference.
Of the 25 coding, predicted loss of function mutations in AJBQM1 and AJBQM2 (Listed in
Supplementary file 1A), only slit3sa1569/+ (exon seven splice acceptor site disruption at amino acid
position 176), segregated with nicotine preference (Figure 4A and Supplementary file 1Ei). None
of the coding, predicted loss of function mutations in AJBQM2 segregated with nicotine preference
and this line was not examined further (Supplementary file 1Eii).
To confirm that loss of slit3 function was related to nicotine seeking behaviour we obtained an
independent family of fish, slit3sa202, carrying a G > T transversion producing a premature stop
codon at amino acid position 163 in the Slit3 protein, from the Sanger Institute. Although not as
marked as in AJBQM1 mutants (hereafter called slit3sa1569), heterozygous slit3sa202 fish showed
enhanced nicotine CPP (p=0.03) compared to wild type siblings (Figure 4C and D). The slit3sa1569
allele affects splicing and slit3sa202 introduces a premature stop codon. Both alleles reside before
the second leucine rich repeat (LRR) domain in the encoded protein (Figure 4B), which is essential
for interaction with ROBO receptor proteins (Brose et al., 1999).
Figure 3. AJBQM1 and AJBQM2 families show increased and decreased nicotine place preference. AJBQM1 and
AJBQM2 siblings, not included in the screen (n = 10 for AJBQM1; n = 14 for AJBQM2), AJBQM1 significantly
differed from the parental strain, Tupfel longfin (TLF) wild type (w/t) saline control (n = 17) and wild type nicotine
exposed fish (n = 7). AJBQM2 differed from wild type nicotine exposed fish but not wild type saline controls.
Different superscript letters indicate significant difference between groups (p<0.05), same superscript letters
indicate no significant differences between groups. Bars indicate Mean + SEM.
The online version of this article includes the following source data for figure 3:
Source data 1. Confirmation of nicotine CPP phenotypes for Figure 3 and Figure 4.
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Characterisation of Slit3sa1569 mutants
SLIT3 is a member of a family of proteins with established axon guidance properties and previously
suggested to be involved in dopaminergic and serotonergic pathfinding (Smidt and Burbach,
2007). Therefore, we performed immunostaining in three-day-old zebrafish larvae and examined the
number of cell bodies and axonal projections of serotonergic (5-HT) and catecholaminergic neurons
in the brain using anti-5-HT and anti-tyrosine hydroxylase (TH) antibodies (Figure 5).
No differences between slit3sa1569 mutant and wild type larvae were observed in the number of
cells labelled by anti-5HT antibody in the raphe nucleus (Mean ± SEM: slit3+/+: 40.2 ± 2.6 vs.
slit3sa1569/sa1569: 47.0 ± 4.7, p=0.23) rostral hypothalamus (slit3+/+: 15.4 ± 2.2 vs. slit3sa1569/sa1569:
19.4 ± 3.8, p=0.38) or inferior hypothalamic lobes (slit3+/+: 76.8 ± 13.5 vs. slit3sa1569/sa1569:
Figure 4. slit3 mutations segregate with nicotine place preference. (A) Segregation of slit3sa1569 mutation with
nicotine seeking. CPP change scores for individual un-mutagenized TLF wild type fish (n = 7) and AJBQM1 fish
(n = 10). Following CPP analysis, fish were genotyped for 25 loss of function mutations contained within the family.
Black dots indicate slit3sa1569/+ heterozygous mutant fish. White dots indicate slit3sa1569+/+ fish. Heterozygosity for
slit3sa1569 segregates with increased nicotine seeking behaviour. (B) Position of ENU-induced mutations in
zebrafish Slit3 protein. slit3sa1569 (A > G transition) disrupts a splice site in intron seven affecting translation at
amino acid 176. slit3sa202 (G > T transversion) introduces a stop codon at amino acid 163. Both mutations truncate
the protein before the leucine rich repeat domain 2 (D2), which interacts with membrane bound ROBO during
SLIT-ROBO signalling. (C) Nicotine preference of slit3sa202 line. slit3sa202/+ fish (n = 18) show increased nicotine
preference compared to wild type TLF controls (n = 8) (p=0.001) and wild type siblings slit3+/+ (n = 14) (p<0.05).
Bars indicate mean + SEM. (D) Segregation of slit3sa202 allele with nicotine seeking. CPP change scores for
individual un-mutagenised TLF wild type parent strain fish (n = 8) and slit3sa202 fish (n = 21). Black dots indicate
slit3sa202/+ heterozygous mutant fish, white dots indicate slit3sa202+/+ fish. Mutations in slit3sa202 co-segregate with
nicotine preference. Heterozygous slit3+/sa202 present increased place preference compared to slit3sa202+/+ siblings
(n = 11).
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Figure 5. Fluorescent immunohistochemistry in three-day old wild type slit3sa1569+/+ and homozygous mutant
slit3sa1569/sa1569. (A–D) Anti-5-HT, (E–M) anti-TH: (A) 5-HT-labelled neurons in wild type zebrafish brain. Circles
indicate regions used for quantification of cell number in rostral hypothalamus (RH), inferior hypothalamic lobes
(HL-R, HL-L) and raphe nucleus (RN). (B) Anti-5-HT labelled cells in slit3 wild type brain, (C) Anti-5-HT labelled cells
in slit3sa1569 homozygous mutant brain. (D) Quantification of anti-5HT labelled cell number in wild type and slit3
Figure 5 continued on next page
Garcı´a-Gonza´lez et al. eLife 2020;9:e51295. DOI: https://doi.org/10.7554/eLife.51295 7 of 33
Research article Neuroscience
94.8 ± 12.9, p=0.36), nor in the number of cells labelled by anti-TH antibody in the diencephalic
dopaminergic cluster (slit3+/+: 209 ± 18 vs. slit3sa1569/sa1569: 140 ± 35, p=0.12) and medulla oblon-
gata interfascicular zone and vagal area (slit3+/+: 196 ± 40 vs. slit3sa1569/sa1569: 124 ± 27, p=0.17).
Similarly, we observed no significant differences in the number of anti-TH labelled axon tracts pro-
jecting to the midline across the three planes examined (slit3+/+: 2.6 ± 2.3 vs slit3sa1569/sa1569:
4.3 ± 1, p=0.53) (Figure 5 and Figure 5—figure supplement 1).
We also looked at the expression patterns using anti-acetylated tubulin antibody along the mid-
line in the ventral forebrain, where slit3 is known to be expressed (Miyasaka et al., 2005). However,
no obvious differences were observed. Staining of slbpty77e/ty77e mutant larvae, known to have fewer
neurons and axonal defects (Petzold et al., 2009) were used as positive control (Figure 5—figure
supplement 1).
Although we did not observe differences between wild type and slit3sa1569 mutants, subtle effects
on circuit formation may not have been detected by our antibody staining. To further characterise
the slit3 phenotype and explore potential functional differences in catecholamine circuitry, we exam-
ined the response and habituation to acoustic startle stimuli in wild type and mutant fish. Habitua-
tion to acoustic startle is known to involve catecholamine signalling and to be sensitive to
dopaminergic/serotonergic antagonists such as amisulpride (Quednow et al., 2006) and, in humans,
is associated with vulnerability to addiction (Loeber et al., 2007; Vrana et al., 2015; Kumari and
Gray, 1999). Five-day-old larvae were subjected to 10 sound/vibration stimuli over a total of 20 s (2
s interval between each stimulus) in the presence of 0, 0.05 mg/L, 0.1 mg/L or 0.5 mg/L amisulpride
in 0.05% dimethyl sulfoxide (DMSO). The distance travelled one second after each stimulus was
recorded for each fish.
Response and habituation to the stimuli was quantified as the percentage of fish moving more
than the mean plus two standard deviations of the mean baseline distance travelled per second
before startle stimulus (mean + 2SD = 4.6 mm) in the first second after each stimulus. Using this cri-
terion – and in line with the habituation response paradigm (Rankin et al., 2009) – a lower percent-
age of fish responded as the number of stimuli increased: 68% of wild type, non-drug-treated
individuals responded to the first stimulus, 81% to the first and/or second stimulus, whereas 16%
responded to the last stimulus (Figure 6B).
In drug-free conditions, there were no differences across slit3sa1569 genotype groups (Figure 6C).
However, when larvae were treated with amisulpride, the habituation to startle responses across
taps was different across genotypes. Amisulpride caused a biphasic dose dependent effect on stimu-
lus response in wild types such that 0.05 mg/L caused an increase in responders across all 10 stimuli,
and 0.5 mg/L caused a decrease (Effect of amisulpride dose p<0.001). A similar pattern was
observed for heterozygous slit3sa1569, but the effect of amisulpride was not significant (p=0.083).
Figure 5 continued
mutant brains No significant differences were observed between wild type and slit3 mutant larvae. (E)
Unprocessed maximum intensity projection of anti-TH-labelled whole mounted wild type zebrafish brain. Circles
indicate areas used for quantification, or in the case of LC-R and LC-L, landmarks used as reference to determine
the extension of the medial longitudinal catecholaminergic tract (MLC) used when quantifying the number of anti-
TH labelled projections to the midline (panels L, M). (F) Cell quantification for diencephalic dopaminergic cluster
(DDC). No significant differences were observed between wild type and slit3 mutant larvae. (G) Cell quantification
for medulla oblongata interfascicular zone and vagal area, and area postrema (MO, AP). No significant differences
were observed between wild type and slit3 mutant larvae. (H–K) Anti-TH labelled wild types and slit3sa1569.
Zoomed-in visualization of diencephalic dopaminergic cluster (H–I) and medulla oblongata interfascicular zone
and vagal area (J–K). (L–M) Quantification of catecholaminergic projections projecting to the midline. Examples of
projections are indicated with yellow arrows. Projections were assessed from posterior to anterior using the locus
coerulus and posterior extent of the raphe nucleus as landmarks (Panel L, yellow line) and from dorsal to ventral
(Panel M, stacks 1–3). Figure 5—figure supplement 1 shows individual planes. n = 5 samples per genotype
group.
The online version of this article includes the following source data and figure supplement(s) for figure 5:
Source data 1. Quantification of anti-5HT and anti-TH labelled cell number and anti-TH labelled axon projections.
Figure supplement 1. Fluorescent immunohistochemistry in three-day old wild type and homozygous mutant
slit3sa1569 labelled with tyrosine hydroxylase (A) and tubulin (B–F).
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Amisulpride dose had no significant effect on stimulus response in homozygous slit3sa1569, that
showed an increase in response to low doses but were less sensitive to inhibition at high doses
(Figure 6D–F). The presence of a slit3sa1569 genotype by amisulpride dose interaction across taps
was confirmed by a three-way interaction in the regression models (p=0.04). The interaction
between dose and stimulus event number was a significant predictor of response in wild type larvae
(p=0.044) and heterozygous larvae (p=0.02) but not in homozygous larvae (p=0.16).
There were no significant differences in locomotion before the first tap stimulus, in magnitude of
the response to the first tap stimulus, nor in total distance moved across all tap stimuli across experi-
mental groups (Figure 6—figure supplement 1) indicating that differences in startle behaviour were
not confounded by differences in locomotion per se.
Adult slit3 sa1569/ sa1569 mutant zebrafish showed a qualitatively different response to inhibition of
CPP by amisulpride compared to wild type siblings, consistent with a persistent difference in sensi-
tivity to this drug. The minimal CPP induced by 5 mM nicotine in wild type fish was prevented by
Figure 6. Habituation response in the presence and absence of amisulpride. (A–B) Response and habituation to
10 stimuli with two seconds interval between stimuli in wild type, drug free zebrafish. Mean distances travelled
were measured in one second time bins. Line indicates 4.6 mm, which corresponds to mean basal distance moved
per second plus 2 standard deviations of the mean and was used to define respondents. The percentage of fish
responding to the stimuli decreases with stimulus/tap number (Main effects of tap number p<0.05) 68% respond
to the first tap; 16% respond to the last tap. Respondents are defined as fish moving more than 4.6 mm. (C)
Proportion of responders across the ten stimuli in drug free individuals from each genotype: there was no
significant effect of genotype on response across taps (p=0.34) or responsiveness (p=0.35) in drug free fish. (D)
Mean percentage of responders across the ten stimuli (± SEM). Data are stratified by slit3sa1569 genotype and
amisulpride dose normalised to response in absence of drug. The effect of amisulpride on habituation varies by
genotype. (E, F) Proportion of individuals responding in each amisulpride dose condition in wild type and
homozygous mutant fish, respectively. The interaction between amisulpride dose and stimulus event number had
a significant effect on the proportion of responsive individuals in wild type individuals (p<0.05) but not
homozygous mutants (p=0.16).
The online version of this article includes the following source data, source code and figure supplement(s) for
figure 6:
Source code 1. Zebrafish habituation to acoustic startle R code.
Source data 1. Response to acoustic startle in the presence and absence of amisulpride.
Figure supplement 1. Average distance moved before (Figure 1A) and during startle stimuli (Figure 1B) in wild
type and slit3sa1569 mutant five-day-old zebrafish larvae.
Garcı´a-Gonza´lez et al. eLife 2020;9:e51295. DOI: https://doi.org/10.7554/eLife.51295 9 of 33
Research article Neuroscience
pre-exposure to 0.5 mg/L amisulpride. Nicotine-induced CPP in slit3sa1569 homozygous mutants was
not affected (Figure 7).
As slit3sa1569 homozygous mutant fish showed altered sensitivity to nicotine and amisulpride, we
examined whether expression of genes previously associated with nicotine dependence was dysre-
gulated in slit3sa1569 mutant larvae using quantitative real-time PCR (qPCR). We included the nico-
tinic receptors and genes from the dopamine receptor family (Huang et al., 2008a; Swan et al.,
2005; Huang et al., 2008b; Sieminska et al., 2009) -drd1 (Huang et al., 2008a), drd2 (Swan et al.,
2005) and drd3 (Huang et al., 2008b)-, and the dopamine transporter dat (Sieminska et al., 2009).
Genes from the adreno-receptor families (adra1 and adra2) were also included due to their links with
nicotine addiction and use as putative targets for smoking treatment (Forget et al., 2010;
Kotagale et al., 2010; Swan et al., 2006). Finally, expression of serotonin receptor genes was
included, again due to their well-established links with nicotine addiction (Kenny et al., 2001;
Levin et al., 2008; de Bruin et al., 2013; Hauser et al., 2014; Bloch et al., 2010).
For several genes (i.e. drd3, chrnb3, htr4, adra2b), up-regulation of gene expression in mutant lar-
vae showed nominal significance (Supplementary file 1H). However, only htr1aa ([F(2,6)=44],
p=0.0003) showed a significant difference across genotypes after correcting for multiple testing
(Figure 8).
Genetic variation at the SLIT3 locus is associated with smoking
behaviour in human samples
We next examined associations between 19 single nucleotide polymorphisms (SNPs) in the human
SLIT3 gene and smoking behaviour in two London cohorts. Two SNPs, rs12654448 and rs17734503
Figure 7. CPP induced by 5 mM nicotine is blocked by 0.5 mg/L dopamine/serotonin antagonist amisulpride in
wild type slit3sa1569+/+ fish but not in slit3sa1569 homozygous mutants. Bars represent mean (+ SEM). (n = 11–14 fish
per group). *Two-way ANOVA followed by post-hoc Tukey tests (p<0.05).
The online version of this article includes the following source data for figure 7:
Source data 1. Inhibition of nicotine CPP by amisulpride.
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Figure 8. Quantitative real-time PCR analysis of five-day-old wild type slit3sa1569+/+, slit3sa1569/+ heterozygous and
slit3sa1569/sa1569 homozygous mutant larvae. Quantitative PCR analysis of gene expression was performed for
members of (A) dopaminergic signalling pathway, (B) adrenoreceptors, (C) serotonin signalling pathway and (D)
nicotinic cholinergic receptors. (Total n=30, 3 samples per experimental group with n=10 embryos per sample).
Only htr1aa ([F(2,6)=44], p=0.0003) showed a significant difference across genotypes after correcting for multiple
testing. *Two-way ANOVA followed by post-hoc Tukey test (p < 0.05).
The online version of this article includes the following source data for figure 8:
Source data 1. Gene expression data for slit3 mutant and wild type zebrafish.
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in high linkage disequilibrium (Figure 9) were associated with level of cigarette consumption
(p=0.00125 and p=0.00227). We repeated the analysis on heavy smokers: rs12654448
(p=0.0003397) and rs17734503 (p=0.0008575) were again associated with cigarette consumption
together with rs11742567 (p=0.004715). The SNP rs11742567 was associated with cigarette con-
sumption in light smokers (<20 cigarettes per day, p=0.003909)) and with quitting. Associations are
reported in Table 1. No other SLIT3 polymorphisms were associated with smoking initiation, persis-
tent smoking or cessation (Supplementary file 1F and G).
We subsequently investigated associations with more detailed smoking phenotypes in the Finnish
twins cohort (Kaprio, 2006; Table 2). Associations were observed between rs17734503 and DSM-IV
nicotine dependence symptoms (p=0.0322) and age at onset of weekly smoking (p=0.00116) and
between rs12654448 and age at onset of weekly smoking (p=0.00105). Associations were seen else-
where between SLIT3 markers and Fagerstro¨m Test for Nicotine Dependence (FTND), cigarettes
smoked each day, sensation felt after smoking first cigarette and time to first cigarette in the morn-
ing. In keeping with the London studies the minor allele was associated with a lower degree of
dependence and decreased cigarette consumption.
The SNPs rs12654448 and rs17734503 are in non-coding domains, therefore it was not possible
to predict loss or gain of function of SLIT3 from the SNP location. No evidence of affecting gene
expression was found as per GTEx database (https://gtexportal.org/home/).
Discussion
The aim of this study was to use forward genetic screening in zebrafish to identify loci affecting
human smoking behaviour. Among 30 mutant zebrafish families screened for CPP, we identified one
family showing increased nicotine preference compared to wild types. Out of the 13 pre-identified
loss-of-function mutations in that family, only one in the slit3 gene co-segregated with the behaviour.
We confirmed the association between slit3 loss of function and increased nicotine preference using
Figure 9. Linkage disequilibrium (LD) plot of SLIT3 SNPs in human smoking association analysis. Numbers within
each square indicate D’ values (white: D’<1, LOD <2; blue: D’=1, LOD <2; pink: D’<1, LOD 2; and bright red:
D’=1, LOD 2). Top part of the figure shows domain organization of the SLIT protein based on the UCSC
Genome Browser (http://genome.ucsc.edu/) in relation to the SNP location. LRR: leucin-rich repeats. EGF:
epidermal growth factor domains. LamG; Laminin G domain. Some intron numbers were added for reference.
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an independent zebrafish mutant line with a different loss of function mutation in slit3. Next, we
established the relevance in humans by identifying two markers in SLIT3 where the presence of the
minor allele was associated with fewer cigarettes smoked each day and with smoking cessation.
Studies in a separate twin cohort showed that these same alleles were associated with DSM-IV nico-
tine dependence symptoms and age at onset of weekly smoking. Taken together these findings sug-
gest that zebrafish can be used to identify genes associated with smoking behaviour in humans and
that variants in the SLIT3 gene are linked in humans with a disruption of SLIT3 function that may
affect propensity to develop tobacco dependence.
Consistent with previous findings in zebrafish and other species (Ponzoni et al., 2014), varenicline
and bupropion inhibited nicotine induced place preference in zebrafish. The pattern of inhibition dif-
fered such that varenicline (partial agonist) showed increasing inhibition at increasing concentrations,
whereas inhibition by bupropion (re-uptake inhibitor) was maximal at 1 mM, decreasing as concentra-
tion increased. The difference in response profile presumably reflects differences in the modes of
action of these two compounds.
Our screening of ENU-mutagenized zebrafish families followed by sibling re-screen is a proof of
principle study that indicates the relevance of zebrafish for human studies and emphasizes the
Table 1. Associations of SLIT3 SNPs with level of tobacco consumption for the London study groups (n = 863).
Regression coefficients, confidence intervals and p-values from linear regression of cigarettes smoked per day (CPD) on minor allele
count for smokers from COPD, asthma and general cohorts, adjusted for age, sex and cohort. b coefficient represents effect of each
additional minor allele. Benjamini-Hochberg cut-off at q-value 0.1 = 0.01053. Associations of SLIT3 SNPs with tobacco consumption in
a subset of heavy smokers (20 cigs/day). Adjusted for age, sex and cohort. (q-value 0.1 = 0.01579). Associations of SLIT3 SNPs in a
subset of light smokers (<20 cigs/day). Adjusted for age, sex and cohort (q-value 0.1 = 0.00526). Association analysis of SLIT3 SNPs
with smoking cessation. Logistic regression of current smokers vs ever smokers controlling for age, sex and cohort. Odds ratio >1 indi-
cates minor allele increases odds of persistent smoking relative to major allele. SE: standard error, L95: lower limit of 95% confidence
interval, U95: upper limit. For all panels, associations in bold remained significant after adjustment for multiple comparisons using a
Benjamini-Hochberg procedure to control false discovery rate at 10%.
Tobacco consumption
Tobacco consumption -
heavy smokers
(20 cigs/day)
Tobacco consumption - light
smokers
(<20 cigs/day) Smoking cessation
SNP P value b SE 95% P value b SE 95% P value b SE 95% OR SE L95 U95 P value
rs10036727 0.629  0.388 0.802 ( 1.960, 1.183) 0.448  0.653 0.860 ( 2.337, 1.032) 0.940  0.051 0.686 ( 1.396, 1.293) 0.947 0.160 0.693 1.295 0.734
rs11134527 0.218 1.014 0.822 ( 0.596, 2.625) 0.327  0.867 0.883 ( 2.599, 0.864) 0.261 0.795 0.705 ( 0.586, 2.176) 0.665 0.165 0.482 0.918 0.013
rs11742567 0.135  1.166 0.779 ( 2.691, 0.361) 0.005  2.346 0.825 ( 3.962,–0.730) 0.004 1.888 0.644 (0.6258, 3.151) 1.586 0.163 1.153 2.183 0.005
rs11749001 0.059 1.972 1.044 ( 0.074, 4.018) 0.873 0.177 1.103 ( 1.985, 2.338) 0.206 1.200 0.944 ( 0.651, 3.051) 0.953 0.206 0.637 1.426 0.817
rs12515725 0.592  0.406 0.756 ( 1.888, 1.076) 0.488  0.565 0.813 ( 2.159, 1.029) 0.278  0.688 0.631 ( 1.925, 0.550) 1.028 0.151 0.765 1.381 0.855
rs12521041 0.904  0.105 0.865 ( 1.801, 1.591) 0.996  0.005 0.942 ( 1.851, 1.841) 0.059  1.354 0.710 ( 2.746, 0.038) 1.554 0.178 1.096 2.205 0.013
rs12654448 0.001  4.241 1.307 ( 6.803, –1.680) 0.0003  4.830 1.334 ( 7.444, –2.216) 0.410  1.034 1.251 ( 3.486, 1.417) 1.625 0.279 0.941 2.808 0.082
rs1345588 0.240  1.268 1.078 ( 3.380, 0.845) 0.253  1.334 1.164 ( 3.616, 0.948) 0.869  0.150 0.907 ( 1.927, 1.627) 1.417 0.222 0.918 2.189 0.116
rs1421763 0.272  0.982 0.894 ( 2.735, 0.770) 0.978  0.027 0.959 ( 1.908, 1.853) 0.162  1.074 0.764 ( 2.571, 0.424) 0.917 0.176 0.649 1.294 0.622
rs1559051 0.961  0.040 0.819 ( 1.644, 1.564) 0.458 0.656 0.882 ( 1.073, 2.384) 0.507 0.455 0.685 ( 0.880, 1.797) 0.919 0.163 0.668 1.265 0.606
rs17665158 0.131 1.338 0.884 ( 0.394, 3.070) 0.236 1.114 0.939 ( 0.727, 2.955) 0.034 1.620 0.758 (0.1354, 3.106) 0.723 0.172 0.516 1.013 0.060
rs17734503 0.002  3.987 1.299 ( 6.534, –1.441) 0.001  4.458 1.325 ( 7.055, –1.861) 0.410  1.034 1.251 ( 3.486, 1.417) 1.616 0.275 0.942 2.773 0.081
rs2938774 0.140 1.101 0.745 ( 0.359, 2.562) 0.528 0.496 0.786 ( 1.044, 2.036) 0.015  1.655 0.674 ( 2.976, –0.333) 0.753 0.148 0.563 1.007 0.056
rs295994 0.714 0.283 0.770 ( 1.227, 1.793) 0.643 0.378 0.813 ( 1.215, 1.971) 0.238  0.796 0.672 ( 2.114, 0.521) 0.799 0.154 0.591 1.082 0.147
rs297886 0.620 0.442 0.890 ( 1.303, 2.187) 0.961  0.048 0.986 ( 1.979, 1.884) 0.489 0.488 0.704 ( 0.891, 1.867) 1.108 0.177 0.784 1.568 0.561
rs3733975 0.909  0.099 0.860 ( 1.784, 1.587) 0.982 0.022 0.934 ( 1.809, 1.852) 0.059  1.354 0.710 ( 2.746, 0.038) 1.488 0.176 1.054 2.101 0.024
rs4282339 0.669  0.434 1.013 ( 2.419, 1.552) 0.942  0.080 1.103 ( 2.241, 2.081) 0.238  1.006 0.849 ( 2.670, 0.658) 0.984 0.203 0.661 1.464 0.936
rs7728604 0.701 0.286 0.744 ( 1.173, 1.745) 0.321 0.827 0.832 ( 0.803, 2.457) 0.654 0.262 0.583 ( 0.880, 1.404) 0.935 0.149 0.698 1.253 0.653
rs9688032 0.948  0.050 0.766 ( 1.551, 1.451) 0.770 0.246 0.839 ( 1.398, 1.890) 0.080  1.076 0.610 ( 2.272, 0.119) 1.066 0.156 0.786 1.446 0.680
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Table 2. Associations between detailed nicotine dependence phenotypes and SLIT3 genotype in a Finnish twin cohort (n = 1715).
Associations of SLIT3 SNPs with DSM-IV nicotine diagnosis, symptoms, Fagerstro¨m scores (FTND), cigarettes smoked each day (CPD),
age of onset of weekly smoking, sensation felt after smoking first cigarette and time to first cigarette in the morning. The three SNPs
that were linked to smoking behaviour in the London cohorts are shown in bold.
DSM-IV ND diagnosis DSM-IV ND symptoms FTND (4) FTND score
SNP b SE P value b SE P value b SE P value b SE P value
rs12654448  0.0343 0.0262 0.190975  0.1839 0.0964 0.056728 0.0526 0.0287 0.066509 0.075 0.1365 0.58286
rs17734503  0.0354 0.0259 0.171821  0.2044 0.0954 0.032199 0.0474 0.0283 0.094383 0.0443 0.135 0.743052
rs11742567 0.0006 0.0163 0.97262  0.0359 0.0601 0.55086 0.0134 0.0179 0.45384 0.0449 0.0851 0.597682
rs17665158 0.0117 0.019 0.538639 0.1536 0.0696 0.027544 0.0178 0.0207 0.391096 0.0935 0.0988 0.344157
rs1345588  0.0031 0.0222 0.889847  0.0389 0.0817 0.634184 0.0578 0.0242 0.01708 0.1901 0.1157 0.100729
rs7728604  0.0049 0.0162 0.761485  0.0442 0.0597 0.459743 0.0004 0.0177 0.980706  0.0261 0.0846 0.757849
rs11134527 0.0296 0.0171 0.084576 0.0927 0.063 0.141369 0.0324 0.0187 0.083498 0.1376 0.0891 0.122807
rs10036727 0.0067 0.0165 0.68406 0.0207 0.0605 0.732266 0.0022 0.018 0.903865 0.046 0.0857 0.591583
rs1559051 0.0249 0.0193 0.198647 0.0492 0.0703 0.484353  0.0433 0.0208 0.037736  0.1011 0.0995 0.309836
rs12515725 0.0072 0.0159 0.6502 0.0277 0.0584 0.635739 0.0586 0.0172 0.000696 0.2482 0.0824 0.002637
rs2938774 0.0042 0.0173 0.80717 0.0096 0.0642 0.881054  0.0157 0.0191 0.41163  0.0173 0.0907 0.848978
rs295994  0.014 0.0171 0.410864  0.0144 0.0622 0.816397  0.016 0.0184 0.38542  0.0985 0.0879 0.262584
rs9688032  0.0174 0.0173 0.31299  0.0347 0.0636 0.585081 0.0234 0.0189 0.216144 0.0626 0.09 0.4869
rs11749001 0.0178 0.0235 0.448278  0.0062 0.0865 0.942516 0.0224 0.0257 0.383552 0.0067 0.1222 0.956097
rs4282339 0.0118 0.0201 0.557544 0.0526 0.0739 0.476216  0.0077 0.0219 0.724058 0.1623 0.1045 0.120641
rs297886  0.0216 0.0171 0.207835  0.045 0.0634 0.478517  0.0256 0.0188 0.173314  0.1354 0.0897 0.131469
rs1421763 0.0079 0.0187 0.671624 0.0178 0.0687 0.795522 0.0641 0.0203 0.001641 0.2582 0.0971 0.007892
rs3733975  0.013 0.0167 0.436903  0.0798 0.0613 0.192755  0.0384 0.0181 0.034371  0.2083 0.0866 0.016295
rs12521041  0.0098 0.0167 0.559173  0.0669 0.0613 0.275274  0.0365 0.0182 0.044962  0.1905 0.0868 0.028295
CPD max CPD Age of onset of weekly smoking First time sensation FTND time to first cigarette
SNP b SE P value b SE P value b SE P value b SE P value b SE P value
rs12654448 -0.3509 0.5669 0.536029  1.0602 0.7743 0.171106 0.7826 0.2384 0.001051  0.0861 0.1423 0.545206 0.0047 0.0802 0.953291
rs17734503 -0.479 0.5608 0.393086  1.2329 0.7657 0.107544 0.7689 0.2362 0.001156  0.1039 0.1406 0.460344 0.0188 0.0795 0.812682
rs11742567 0.0179 0.3532 0.959588  0.4621 0.4823 0.338159 0.0965 0.1493 0.518066  0.1003 0.0884 0.256427  0.0216 0.05 0.665265
rs17665158 0.8135 0.4096 0.047191 1.5424 0.5587 0.005828 0.0562 0.1732 0.745385 0.2476 0.1027 0.01603  0.0884 0.058 0.12787
rs1345588 0.294 0.4805 0.54066 0.3968 0.6562 0.54542 0.0989 0.2031 0.626431  0.0618 0.1204 0.607606  0.1303 0.068 0.055678
rs7728604 -0.0772 0.3511 0.825888 0.0691 0.4795 0.885363  0.0261 0.1486 0.860643  0.029 0.0875 0.740682  0.0193 0.0497 0.6978
rs11134527 0.1831 0.3705 0.621187 0.7441 0.5057 0.141392  0.2347 0.1563 0.133517 0.1142 0.093 0.21965  0.1089 0.0523 0.037681
rs10036727 0.1482 0.3557 0.67697 0.4246 0.4858 0.382161  0.0456 0.1507 0.762197 0.0289 0.0896 0.74711  0.0639 0.0504 0.205061
rs1559051 -0.4816 0.413 0.243693  0.4779 0.5641 0.397066 0.1437 0.175 0.411533  0.0289 0.1045 0.782381 0.0731 0.0586 0.212174
rs12515725 0.5491 0.3429 0.10948 0.7708 0.4684 0.100032  0.1629 0.1452 0.26192  0.0368 0.0865 0.670165  0.1385 0.0485 0.00434
rs2938774 -0.2796 0.377 0.45835 0.1945 0.5149 0.70567  0.0575 0.1598 0.718862 0.043 0.0933 0.645221  0.0136 0.0533 0.797909
rs295994 -0.2793 0.3651 0.444276  0.2585 0.4988 0.604451 0.1543 0.1548 0.318928 0.0625 0.0926 0.499881 0.0527 0.0517 0.307869
rs9688032 0.2452 0.3738 0.511921 0.4211 0.5107 0.409766  0.1142 0.1584 0.471283  0.2227 0.0937 0.01755  0.0517 0.0531 0.329867
rs11749001 -0.0301 0.5078 0.952789 0.0574 0.6939 0.934054  0.1994 0.2147 0.353064 0.1497 0.1274 0.240255 0.0075 0.0718 0.916823
rs4282339 0.4086 0.434 0.346592 0.3083 0.593 0.603197 0.0952 0.1836 0.603958  0.0394 0.1084 0.716204  0.0524 0.0614 0.394221
rs297886 -0.1375 0.3727 0.712273  0.4782 0.5091 0.347622 0.1262 0.1575 0.423104 0.0519 0.0928 0.576255 0.0632 0.0527 0.230861
rs1421763 0.5585 0.4037 0.166723 0.6702 0.5515 0.224417  0.1481 0.1706 0.385475  0.0799 0.1018 0.432497  0.1269 0.0571 0.026442
Table 2 continued on next page
Garcı´a-Gonza´lez et al. eLife 2020;9:e51295. DOI: https://doi.org/10.7554/eLife.51295 14 of 33
Research article Neuroscience
advantage of first using a screen with a low number of individuals per family to increase efficiency.
The classic three generation forward genetic screen examines phenotypes in groups of 20 or more
individuals from each family (Lawson and Wolfe, 2011). Logistical considerations make it difficult to
apply such an approach to adult behavioural screens. Our approach increases efficiency by initially
screening a small number of individuals from a large number of families and only selecting those
families that occur at the extremes of the distribution for further analysis. Although in this study we
were able to confirm phenotypes using a relatively small population of siblings, re-screening of a
larger number would increase the power of the analysis and allow more subtle phenotypes to be
identified.
One limitation of our forward genetic approach is that a large number of genes are duplicated in
zebrafish due to the teleost tetraploidization; ENU-mutagenesis in one copy may not be sufficient to
produce behavioural changes due to genetic compensation from the other copy of the same gene.
Slit3 is present as a single copy in the zebrafish genome which may have facilitated our ability to
identify its role in responses to nicotine. However, arguably the most significant consequence of the
teleost tetraploidization is the temporal and spatial specific expression of the gene duplicates. Spa-
tial and/or temporal differences in gene expression patterns may offset concerns regarding compen-
sation, and offer great potential to study region-specific functionality.
We identified a loss of function mutation in the zebrafish slit3 gene associated with increased nic-
otine place preference and confirmed the phenotype in an independent line. SLIT molecules bind to
ROBO receptors through a highly conserved leucine-rich repeat (LRR) domain (Morlot et al., 2007).
In the AJBQM1 (slit3sa1569) line the loss of function mutation causes a truncation at amino acid 176
and in the slit3sa202 line at amino acid 163. These are immediately adjacent to the LRR2 domain
responsible for SLIT3’s functional interaction with ROBO proteins (Morlot et al., 2007) and would
therefore be predicted to lead to formation of non-functional proteins. Initially identified as a family
of axon guidance molecules, SLIT proteins are known to be expressed in a range of tissues and, by
regulating cell polarity, to play major roles in many developmental process including cell migration,
proliferation, adhesion, neuronal topographic map formation and dendritic spine remodelling
(Blockus and Che´dotal, 2014). In vitro SLIT proteins bind promiscuously to ROBO receptors sug-
gesting that the proteins may co-operate in vivo in areas in which they overlap. However, their
restricted spatial distributions, particularly of SLIT3 in the central nervous system (Marillat et al.,
2002) suggest the individual proteins play subtly different roles in vivo.
Despite its neuronal expression, the most prominent phenotype seen in Slit3 deficient mice is
postnatal diaphragmatic hernia (Yuan et al., 2003; Liu et al., 2003) with no obvious neuronal or
axon pathfinding defects having been reported. Similarly, we did not detect any major differences in
axon pathfinding nor in number of serotonergic and catecholaminergic cells in slit3 mutant zebrafish
larvae. As suggested previously (Long et al., 2004) it may be that overlap of expression with other
slit molecules compensates for loss of slit3 in the brain preventing gross neuronal pathfinding
defects. However, subtle differences in circuit formation and/or axon branching may have escaped
our analysis.
As our antibody staining may not have detected subtle, functionally important differences in
dopaminergic and/or serotonergic circuit formation we examined the impact of the dopaminergic
and serotonergic antagonist amisulpride on the acoustic startle response, a behaviour associated
with vulnerability to addiction and known to be sensitive to modulation by dopaminergic antagonists
in zebrafish as well as mammals (Quednow et al., 2006; Halberstadt and Geyer, 2009;
Burgess and Granato, 2007). Although the binding affinity of amisulpride in zebrafish has not been
examined, reported behavioural effects (Tran et al., 2015) are consistent with binding characteristics
and behaviours seen in mammalian species. In mammals, amisulpride binds to D2/3 pre-and post-
synaptic receptors with greater affinity at presynaptic than post-synaptic receptors
Table 2 continued
DSM-IV ND diagnosis DSM-IV ND symptoms FTND (4) FTND score
rs3733975 -0.7784 0.3597 0.030606  1.0555 0.4911 0.031758 0.0902 0.1521 0.553335  0.2932 0.0896 0.001085 0.1373 0.0509 0.007035
rs12521041 -0.7312 0.3602 0.042534  0.8864 0.492 0.071805 0.0522 0.1523 0.731943  0.3129 0.0897 0.000499 0.1257 0.051 0.01373
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(Schoemaker et al., 1997; Perrault et al., 1997). Presynaptic D2 receptors in mammals act as autor-
eceptors and inhibit the synthesis and subsequent release of dopamine. D2/3 postsynaptic receptors
are coupled to Gi/o G proteins mediating inhibitory neurotransmission (Beaulieu and Gainetdinov,
2011). Treatment of rodents with D2/3 receptor antagonists leads to biphasic effects on locomotion
such that low doses inhibit locomotion via pre-synaptic D2/3 autoreceptors, and high doses increase
locomotion via post-synaptic D2/3 receptors (Millan et al., 2004). Treatment of adult zebrafish with
amisulpride has a similar biphasic dose-dependent effect on locomotion such that low doses inhibit
locomotion and high doses increase locomotion (Tran et al., 2015). These findings suggest that ami-
sulpride has similar binding affinities at D2/3 receptors in fish as in rodents and imply the existence
of pre-and post- synaptic D2/3 receptors with similar functional properties.
Our finding that high concentrations of amisulpride increased habituation to acoustic startle in
wild type fish is in agreement with the effect of amisulpride in humans (Quednow et al., 2006). A
biphasic dose-dependent effect of amisulpride on habituation in wild type larvae suggests the
involvement of both pre- and post- synaptic dopamine receptors. Inhibition of presynaptic receptors
at low dose leading to increased responsiveness (reduced habituation), and inhibition of postsynap-
tic receptors at high doses causing reduced responsiveness (increased habituation). In contrast to
results in wild type fish, slit3sa1569 mutant larvae showed decreased habituation in the presence of
both high and low dose amisulpride, suggesting a reduction of sensitivity to amisulpride at post-syn-
aptic sites, possibly related to the marginal increase in dopamine D3 receptors in slit3 mutants. Dif-
ferential sensitivity to amisulpride was also seen at adult stages, where amisulpride inhibited
nicotine-induced CPP in adult wild type fish but not in slit3sa1569 mutants. These findings are consis-
tent with a disrupted dopaminergic system, and/or disrupted interactions between dopaminergic
and serotonergic systems caused by slit3 loss of function.
Although our results are consistent with differences in dopaminergic signalling, differential sensi-
tivity to actions of amisulpride at serotonergic receptors cannot be ruled out: amisulpride also acts
as an antagonist at Htr7 and Htr2b receptors with affinities approximately four times lower than at
dopaminergic receptors. In mice, acoustic startle is sensitive to inhibition at Htr2b sites and genetic
ablation of the Htr2b gene induced a reduction in startle amplitude and a deficit in prepulse inhibi-
tion of the startle reflex in loss of function mice (Pitychoutis et al., 2015). Loss of function of Htr7
has no effect on acoustic startle or pre-pulse inhibition of acoustic startle in mice (Semenova et al.,
2008).
Although gene expression analyses revealed subtle up-regulation in several receptors - including
drd3, chrnb3, adra2b and htr4 - in slit3 mutants, significant difference was only seen for the htr1aa
receptor subtype. Zebrafish possess two homologues of the Htr1a gene, htr1aa and htr1ab, with
overlapping expression domains (Norton et al., 2008). The observation of increased htr1aa expres-
sion in slit3 mutants is of interest: Serotonergic signalling has been previously linked to drug reward
processes including nicotine use and dependence (Fletcher et al., 2008; Olausson et al., 2002).
Manipulations which decrease brain serotonin neurotransmission (e.g., a neurotoxic serotonin deple-
tion or a lasting serotonin synthesis inhibition) elevate self-administration of several different drugs
including nicotine in rats (Olausson et al., 2002; Roberts et al., 1994; LeMarquand et al., 1994).
Compounds that facilitate serotonin neurotransmission, such as selective serotonin reuptake inhibi-
tors, decrease nicotine intake (Opitz and Weischer, 1988) however, the HTR1A specific antagonist
WAY100635 has also been reported to block nicotine enhancement of cocaine and methamphet-
amine self-administration in adolescent rats (Dao et al., 2011). Nicotine increases serotonin release
in the striatum, hippocampus, cortex, dorsal raphe nucleus (DRN), spinal cord and hypothalamus
(Seth et al., 2002). The effects in the cortex, hippocampus, and DRN involve stimulation of Htr1a
receptors, and in the striatum, Htr3 receptors. In the DRN, Htr1a receptors play a role in mediating
the anxiolytic effects of nicotine. In contrast, in the dorsal hippocampus and lateral septum, these
same receptors mediate its anxiogenic effects. Further, pharmacological studies in rodents have
shown that the Htr1a receptor antagonists WAY100635 and LY426965 alleviate the anxiety-related
behavioural responses induced by nicotine withdrawal (Rasmussen et al., 1997; Rasmussen et al.,
2000; Harrison et al., 2001). Although it is possible that an anxiolytic effect of nicotine contributed
to the increased nicotine-induced place preference, preliminary assessment of anxiety-like responses
(tank diving) in slit3 mutants, where mutants show decreased anxiety-like behaviour (n.s), argue
against this.
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It is perhaps of particular interest that it is a homologue of the HTR1A receptor that is up-regu-
lated in slit3 mutants. HTR1A is the major inhibitory serotonergic receptor in mammalian systems. In
mammals, it is present as autoreceptors on cell bodies and dendrites in the raphe nucleus and as
post-synaptic heteroreceptors in brain regions implicated in mood and anxiety such as prefrontal
cortex, hippocampus and amygdala. Projections from the raphe release serotonin throughout the
entire forebrain. and brainstem and modulate a range of activities with additional raphe nuclei also
providing innervation to the midbrain (see Garcia-Garcia et al., 2014 for review). Interaction
between HTR1A receptor and dopaminergic signalling are well established. Systemic administration
of HTR1A receptor agonists leads to increased dopamine transmission in the nigrostrial pathway,
ventral tegmental area and frontal cortex (Garcia-Garcia et al., 2014; Bantick et al., 2001).
Although the mechanism underlying this increased dopamine transmission is not clear in all areas,
the likely mechanism is by action on autoreceptors in the raphe so inhibiting serotonergic projections
and disinhibiting dopaminergic transmission (Bantick et al., 2001). Within the nucleus accumbens, a
key area in drug reward, HTR1A agonists have little effect on dopamine release under baseline con-
ditions, but inhibit amphetamine induced release (Ichikawa et al., 1995). Further evidence for inter-
actions between dopaminergic D2 receptor systems and HTR1A receptor signalling come from
studies of atypical neuroleptics for the treatment of schizophrenia. Considerable evidence suggests
that the balance between the properties of D2 receptors and HTR1A receptors influences the profile
of action of these drugs in preclinical models (Newman-Tancredi, 2010; Newman-Tancredi and
Kleven, 2011). Whilst synergistic effects of atypical neuroleptics may enhance dopamine release via
inhibition of D2 autoreceptors and secondarily via disinhibition of projections from the raphe, it has
been suggested (Łukasiewicz et al., 2016) that association of D2 receptors and HTR1A in functional
heterodimers that exhibit properties distinct to either G protein coupled receptor may also be
involved. Such an interaction is seen between D2 receptors and adenosine A2a receptors both in
vitro and in vivo and has been reported for D2 receptors and HTR1A in vitro (Łukasiewicz et al.,
2016). Whilst speculative, it is also potentially of relevance that HTR1A protein expression is upregu-
lated in the brains of schizophrenics (Carrard et al., 2011) and variants in both HTR1A and SLIT3 are
associated with psychiatric disorders (Shi et al., 2004; Glessner et al., 2010; Cukier et al., 2014),
known to involve dopaminergic and serotoninergic pathways.
The mechanism by which loss of function in slit3 leads to increased htr1aa expression and dis-
rupted dopaminergic signalling in zebrafish mutants is yet to be established. However, HTR1A is up-
regulated in conditions of reduced serotonergic signalling in other systems (Garcia-Garcia et al.,
2014; Chen et al., 1998). Loss of serotonergic signalling from the DRN affects dopaminergic axonal
outgrowth to the rat medial prefrontal cortex at developmental stages (Benes et al., 2000) such
that lesioning of the DRN at neonatal stages results in significant increase in dopaminergic fibres.
These effects are stage specific, raising the possibility that, although we did not detect any differen-
ces in catecholamine axon projections at three days post fertilisation, more detailed analysis at later
stages of development would reveal significant differences. The observation that slit3 is strongly
expressed in the posterior raphe nucleus overlapping with htr1aa expression supports interaction
between these two systems. Although detailed co-expression studies have not been performed,
each of the other genes found to have marginal changes in expression also show overlapping
expression with slit3 (Miyasaka et al., 2005; Norton et al., 2008; Boehmler et al., 2004;
Ackerman and Boyd, 2016).
Thus, our findings of an increase in htr1aa expression, altered sensitivity to amisulpride and
altered nicotine CPP support a role for slit3 signalling in the formation of dopaminergic and seroto-
nergic pathways involved in responses to nicotine.
There are limitations to our findings: we used zebrafish of various ages in different experiments.
While this confirms that loss-of-function in slit3 alters behaviour from early life to adulthood, sug-
gesting a developmental role, mechanisms underlying the two behavioural phenotypes may differ.
We used whole embryos for the qPCR study so changes in expression in non-neuronal tissue may
contribute to the observed differences, further, expression of genes in one tissues may mask
changes of expression in another. In addition, we only examined a limited number of receptors and
transporters for key neurotransmitter pathways. Important differences in other transmitter pathways
and neurotransmitter metabolism may have been missed. We confirmed the translational effects of
SLIT3 gene variants in a human study, and the association was validated in a second, independent
cohort. The sample sizes used in the human studies are small in comparison with those used in
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human discovery studies, however we used the two human studies to validate the findings in fish
and analysed only a small set of SNPs focussed on just one gene which minimises the chance of type
one error. Analyses were also corrected for multiple comparisons. The Finnish cohort was not used
as a formal replication of the findings in the London cohort but instead to explore the effects of
genetic variation on richer and more informative smoking phenotypes.
Associations between SLIT3 and aspects of smoking phenotype have also been found in previous
GWAS (https://atlas.ctglab.nl) (Watanabe et al., 2019). However, larger studies would be necessary
to obtain greater precision on estimates of the effect size. Further studies are also required to deter-
mine the effects of genetic variation in SLIT3 on anatomical pathways in the human brain and their
functioning with view to identifying people who are at high risk of developing dependence. This
could be achieved by using imaging techniques to study brain activation in response to smoking
related cues in smokers who have the SLIT3 polymorphisms linked to smoking (particularly
rs12654448).
To our knowledge, this is the first report of a forward behavioural genetic screen in adult zebra-
fish successfully predicting a novel human coding genetic region involved in a complex human
behavioural trait. Taken together, these results provide evidence for a role for SLIT3 in regulating
smoking behaviour in humans and confirm adult zebrafish as a translationally relevant animal model
for exploration of addiction-related behaviours. Further work analysing the cellular processes
affected as a result of the slit3 mutation may provide useful targets when designing tailored treat-
ments to aid smoking cessation.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Genetic reagent
(Danio rerio)
slit3 Sanger Institute sa202 Generated by ENU
mutagenesis. Soon to
be available from
ZIRC zebrafish
resource centre
Genetic reagent
(Danio rerio)
slit3 Sanger Institute sa1569 Generated by ENU
mutagenesis. Soon
to be available from
ZIRC zebrafish
resource centre
Strain, strain
background
(Danio rerio)
Tupfel Sanger Institute Tubingen longfin Wild type strain, now
available from the
ZIRC zebrafish
resource centre
Antibody anti-5-HT
(Rabbit polyclonal)
Sigma Cat#S5545, IHC (1/200)
Antibody anti-tyrosine
hydroxylase
(mouse monoclonal)
Abcam Cat# AB152 IHC (1/1000))
Chemical
compound
Amisulpride Tocris C2132 0.05–0.5 mg/L
Chemical
compound
varenicline sigma PZ0004 10-20micromolar
Chemical
compound
bupropion Sigma B1277 1–10 micromolar
Chemical
compound
Nicotine
hemisulphate
Sigma N1019 5–10 micromolar
Animals
All in vivo experimental work was carried out following consultation of the ARRIVE guidelines
(NC3Rs, UK). Required sample size was estimated following pilot studies to determine effect sizes,
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and power calculations (beta = 0.8, alpha = 0.05). All animals were selected at random from groups
of conspecifics for testing.
Generation of F3 families of ENU-mutagenised fish
Wild type and ENU-mutagenized Tupfel longfin (TLF) fish were obtained from the Sanger Institute,
as part of the Zebrafish Mutation Project which aimed to create a knockout allele in every zebrafish
protein-coding gene (https://www.sanger.ac.uk/resources/zebrafish/zmp/). At the Sanger, ENU-
mutagenized TLF F0 males were outcrossed to create a population of F1 fish heterozygous for ENU-
induced mutations. Due to the high ENU mutation rate (1/300 kb in F1 fish) and homologous recom-
bination when F1 gametes are generated, all F2 were heterozygous for multiple mutations. F2 fami-
lies, each generated from a separate F1 fish, were imported from the Sanger Institute to Queen
Mary University of London (QMUL).
At QMUL a single male and female fish from each F2 family were inbred to generate 30 F3 fami-
lies that would be 25% wild type, 50% heterozygous and 25% homozygous mutant for any single
mutation, assuming Mendelian genetics. Based on exome sequencing data from the F1 generation
performed at the Sanger, each F3 family contained 10–20 known predicted loss of function exonic
mutations, approximately 100 non-synonymous coding mutations and approximately 1500 unknown
mutations in non-coding domains across the entire genome (Kettleborough et al., 2013). Breeding
scheme is detailed in Figure 10.
Fish maintenance
Fish were housed in a recirculating system (Tecniplast, UK) on a 14 hr:10 hr light:dark cycle (08:30–
22:30). The housing and testing rooms were maintained at ~25–28˚C. Fish were maintained in aquar-
ium-treated water and fed three times daily with live artemia (twice daily) and flake food (once). All
procedures were carried out under license in accordance with the Animals (Scientific Procedures)
Act, 1986 and under guidance from the local animal welfare and ethical review board at QMUL.
Conditioned place preference (CPP)
All fish were age and weight matched for all behavioural analysis and were approximately 5 months
old, weighing 0.2–0.25 g at the start of testing. Following habituation and determination of basal
preference, animals were conditioned to 5 mM nicotine (Sigma, Gillingham, UK Catalogue number:
N1019) over three consecutive days and assessed for a change in place preference the following
day. 5 mM nicotine was used because it was predicted to induce a minimum detectable change in
place preference based on results of previous studies (Kily et al., 2008; Kedikian et al., 2013). This
minimal effective dose was used to avoid possible ceiling effects if using a higher concentration.
CPP was assessed as described previously (Kily et al., 2008; Brock et al., 2017; Parker et al.,
2016): The testing apparatus was an opaque 3 L rectangular tank that could be divided in half with a
Perspex divider. Each end of the tank had distinct visual cues (1.5 cm diameter black spots versus
vertical 0.5 cm wide black and white stripes, matched for luminosity). After habituation to the appa-
ratus and handling, we determined the basal preference for each fish: individual fish were placed in
the tank for 10 min and the time spent at either end determined using a ceiling mounted camera
and Ethovision tracking software (Noldus, Wageningen, NL). Any fish showing >70% preference for
either end was excluded from further analysis (between 10% and 20% of fish). Fish were then condi-
tioned with nicotine in the least preferred environment for 20 min, on three consecutive days: Each
day each fish was restricted first to its preferred side for 20 min in fish water and then to its least pre-
ferred side with nicotine or, if a control fish, vehicle (fish water) added, for another 20 min. After 20
min in the nicotine (or vehicle)-paired environment each fish was returned to its home tank. After 3
days of conditioning, on the following day, fish were subject to a probe trial whereby each fish was
placed in the conditioning tank in the absence of divider and the time spent at either end of the
tank over a 10 min period was determined as for assessment of basal preference. The change in
place preference was determined as the proportion time spent in the nicotine-paired zone during
the probe trial minus the proportion time spent in the nicotine-paired zone during basal testing. The
CPP procedure has been used and validated previously with nicotine as well as other drugs
(Kily et al., 2008; Brock et al., 2017; Parker et al., 2016) .
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Data analysis: Change in preference score was calculated as proportion time spent in drug paired
stimulus after conditioning minus proportion time spent in drug paired stimulus before conditioning.
Population means between generations were compared using independent two-sample t-tests, and
effect-sizes ascertained using Cohen’s d (Cohen, 1992). For the rescreen of outlier sibling families
and slit3sa202 line, mutant lines were compared with wild type controls using an independent two-
sample t-test.
CPP in the presence or absence of antagonists
To assess the ability of compounds varenicline (Sigma, Gillingham, UK, PZ0004), buproprion (Sigma,
Gillingham, UK, B1277) or amisulpride (Tocris, Bristol, UK, C2132) to inhibit subjective effects of
Figure 10. Zebrafish breeding scheme to generate F3 families. F2 ENU-mutagenized zebrafish, heterozygous for multiple mutations across the entire
genome were obtained from the Wellcome Sanger Institute as part of the Zebrafish Mutation Project. At QMUL, heterozygous F2 fish were incrossed to
generate 30 F3 families, each containing 10–20 nonsense or essential splice site mutations and about 1500 additional exonic and intronic point
mutations. F3 Families were arbitrarily numbered 1–30. Expected mutation rate and type of mutations in coding regions are specified on the right hand
side.
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nicotine a modified version of the CPP procedure was used (Papke et al., 2012). In this modified
version, following habituation and establishment of basal preference, each day each fish was
restricted first to its preferred side for 20 min in fish water and then removed from the conditioning
tank and transferred to a tank containing the appropriate concentration of test compound or fish
water (plus carrier where required) for 10 min. After 10 min the fish was returned to its least pre-
ferred side in the conditioning tank with nicotine or, if a control fish, vehicle (fish water) for another
20 min. After 20 min in the nicotine (or vehicle)-paired environment, each fish was returned to its
home tank. After three days of conditioning to nicotine in the presence or absence of test com-
pound, on the following day, fish were subject to a probe trial whereby each fish was placed in the
conditioning tank in the absence of divider and the time spent at either end of the tank over a 10
min period determined. To assess the ability of varenicline (0–20 mM) or buproprion (0–10 mM) to
inhibit subjective effects of nicotine in wild type fish, fish were incubated in the presence and
absence of increasing doses of test compound (or vehicle) for 10 min before conditioning to 10 mM
nicotine. Statistical analysis was performed using a univariate analysis of variance (ANOVA), followed
by Tukey’s post hoc test.
To test the effect of amisulpride on nicotine-induced CPP in wild type and slit3sa1569 mutant fish,
fish were incubated in the presence or absence of 0.5 mg/L amisulpride for 10 min before condition-
ing to 5 mM nicotine. We selected 0.5 mg/L amisulpride as this concentration has been shown to
impact behaviour in adults previously (Tran et al., 2015) and wild type and homozygous mutants
were found to be differentially sensitive to the effect of this concentration on acoustic startle
response. Although previous studies with amisulpride in adult zebrafish used a pre-incubation period
of 30 min, to be consistent with our analysis of inhibitory effects of varenicline and bupropion, and
to reduce the possibility of prolonged confinement in a small volume of drug affecting stress levels
which may confound results, we used a preincubation period of 10 min. Two-way ANOVA was per-
formed with genotype (slit3+/+ and slit3sa1569/sa1569) and treatment (control, nicotine, nicotine+-
amisulpride) as independent variables. Values of p<0.05 were considered significant.
Breeding and selection to assess heritability of nicotine-induced place
preference
To test whether nicotine preference is heritable, fish falling in the upper and lower deciles of the
‘change in place preference’ distribution were kept for analysis and further breeding. Individuals
were bred (in-cross of fish from the upper decile and in-cross of fish from the lower decile done sep-
arately) and their offspring screened for CPP (Second Generation CPP analysis). The same approach
was repeated again: fish at the extremes of the Second Generation CPP distribution curve were
selected and in-crossed, and their offspring were used to perform a Third Generation CPP analysis.
Identification of ENU-induced mutations influencing nicotine place
preference
To investigate whether ENU-induced mutations affect fish sensitivity to the rewarding effects of nico-
tine, candidate families were selected when the 3–4 fish from a family tested clustered together at
one or other extreme of the change in preference distribution curve. To confirm the genetic effect
on the CPP phenotype in candidate families, all remaining siblings of that family were assessed for
nicotine induced CPP, along with non-mutagenized TLF control fish, to confirm the genetic effect on
the phenotype. The experimental team and technical staff were blind to the fish genotype.
Candidate mutations, obtained from exome sequencing on F1 fish, were assessed for co-segrega-
tion with behaviour using site specific PCR (Hamajima et al., 2000) on genomic DNA. Once a co-
segregating candidate mutation was identified, larvae from an independent line carrying a predicted
loss of function allele in the same gene were obtained from the Sanger Institute (slit3sa202) to confirm
the association. Heterozygous slit3sa202/+ and sibling slit3+/+ larvae were reared to adulthood and
assessed for nicotine-induced CPP as described above. All fish were fin clipped and genotyped fol-
lowing CPP.
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Zebrafish genomic DNA extraction
Genomic DNA was extracted from fin-clips using QIAGEN DNeasy Blood and Tissue Kit (Qiagen,
Manchester, UK) according to manufacturer’s instructions. Samples were eluted into distilled water
and stored at  20˚C until later use.
Site-specific polymerase chain reaction
Allele-specific PCR SNP assays were used for genotyping F3 individuals for mutations known to be
present in the ENU-mutagenized F1 generation. Four primer pairs were designed to carry out PCR
genotyping as previously described (Hamajima et al., 2000). The list of loss-of-function mutations in
the AJBQM1 and AJBQM2 lines is detailed in Supplementary file 1A. For each line, a primer was
designed with 3’ complementary to the ENU-SNP with a second primer ~100 bp downstream. The
second pair had one primer with 3’ complementary to the wild type base with a second primer ~200
bp upstream. The resulting PCR results in a 300 bp fragment that spans the region and acts as an
internal control for the PCR plus one 100 bp fragment if homozygous for the mutation, 2 bands of
100 bp and 200 bp if heterozygous, and one 200 bp fragment if homozygous wild type. The 4-
primer groups were designed with melting temperatures as close as possible using the NCBI primer
design tool and were ordered from Eurofins, MWG operon (Ebersberg, DE).
Characterization of larvae
Antibody staining
In order to visualize axonal pathways, fluorescent immunohistochemistry was carried out in three day
old embryos from wild type slit3+/+, and homozygous mutant slit3sa1569/sa1569 in-crosses. To prevent
skin pigmentation, embryos were incubated in 0.2 mM of 1-phenyl 2-thiourea (Sigma, Gillingham,
UK) from 24 hr after fertilization. At three days, they were fixed in 4% paraformaldehyde (Sigma, Gil-
lingham, UK) to avoid tissue degradation. For the immunostaining, rabbit polyclonal anti-tyrosine
hydroxylase primary antibody (1:200; Sigma, Gillingham, AB152), rabbit polyclonal anti-serotonin
(5HT) antibody (1:200, Sigma, Gillingham, S5545) and mouse anti-acetylated tubulin monoclonal
antibody (1:1000; Sigma Gillingham, UK, T6793) were used. The three primary antibodies were
detected with Alexa 546-conjugated secondary antibodies (1:400; Fisher Scientific, Loughborough,
UK A11010). Whole-mount immunohistochemistry and mounting was performed as described previ-
ously (Driever et al., 2012).
Confocal microscopy imaging and analysis
Images were acquired using a Leica SP5 confocal microscope. Confocal z-stacks were recorded
under the same conditions using diode laser and images were processed under ImageJ environ-
ment. Areas of interest for quantification were isolated, making sure that for all the individuals the
same number of Z stacks, (covering the same dorsal/ventral distance) were included. The number of
cells was quantified using the ImageJ plugin ‘3D Objects counter’ (https://biii.eu/3d-objects-
counter). To quantify the number of catecholaminergic axons crossing the midline, a line was drawn
from the Medulla oblongata interfascicular zone and vagal area to the locus coeruleus (Figure 5—
figure supplement 1). Every 10 stacks (~7.6 microns), the number of intensity peaks (defined as grey
value intensity >20) was measured. Unpaired t-tests were calculated to assess genotype differences
in the number of cells and intensity peaks.
Startle response in the presence or absence of amisulpride
Five-day-old larvae, generated from adult slit3 wild type and homozygous mutant (slit3sa1569/sa1569)
fish as for quantitative PCR, were individually placed in 24 well plates. In the drug-free condition,
each well contained 300 mL system water and 0.05% of dimethyl sulfoxide (DMSO, Sigma, Gilling-
ham, UK). In the pharmacological conditions, serial dilutions of the dopaminergic and serotonergic
antagonist amisulpride (Tocris, Bristol, UK, 71675-86-9) were prepared to give final concentrations of
0.05 mg/L, 0.1 mg/L or 0.5 mg/L amisulpride in 0.05% DMSO. Amisulpride concentrations were cho-
sen based on previous studies in zebrafish (Tran et al., 2015) and correspond to 50, 100 and 500
times its Ki value for the D2 receptor in mammals (Schoemaker et al., 1997; Perrault et al., 1997).
To ensure that larvae were exposed to the drug for the same amount of time, amisulpride was
added 15 min before undertaking the experiment. Care was taken regarding the distribution of
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concentrations and genotypes to ensure that experimental groups were randomly distributed in the
plates. Plates were placed in a custom-made filming tower with a tapping device that applied 10
sound/vibration stimuli with two seconds interval between them. The setup for this device has been
described elsewhere (Parker and Brennan, 2016). Larval movement was recorded using Ethovision
XT software (Noldus Information Technology, Wageningen, NL) and data were outputted in one sec-
ond time-bins. Three technical replicates were performed (three different days) with three 24 well
plates assayed each day.
For each fish, distance travelled (mm) during one second after each tap was recorded. All videos
used to evaluate responses were checked for tracking errors. Any points where tracking errors were
detected were removed. In total 105 points (31 wild type, 33 heterozygous, 41 homozygous) out of
5460 were removed due to tracking errors. We also excluded individuals that failed to respond to all
10 taps using the criteria defined below. 39 wild type, 38 heterozygous, and 39 homozygous individ-
uals were removed (a total of 115 individuals out of 546).
To evaluate how amisulpride dose and slit3 genotype affect habituation to the startle stimulus,
we defined a response/non-response status for each fish. Threshold for response status was defined
as mean distance moved per second before the first stimulus (basal distance) plus two standard devi-
ations (SD) of the mean. Since genotype was not a significant predictor of basal distance travelled –
confirmed by a linear mixed effect model with basal distance as the response variable and genotype
as the explanatory variable (p=0.123), we calculated the population mean and SD of basal distance
for the three slit3 genotypes together (mean = 1.4 mm, SD = 1.6, mean+2SD = 4.6 mm). Each fish
was assigned as ‘responder’ if it moved more than the threshold in the first second after the stimulus
or as ‘non-responder’ if it did not.
The percentage of fish responding to stimulus together with amisulpride dose, stimulus event
number and genotype group were modelled in a beta regression conducted using the R package
‘betareg’. The proportion of individuals responding was the response variable and the three-way
interaction between amisulpride dose, genotype, and stimulus event number was the explanatory
variable. To determine whether this interaction was a significant predictor of individual responsive-
ness (indicating that genotypes varied in how amisulpride dose affected their habituation to
repeated stimuli), likelihood ratio tests for nested regression models were performed. Results of all
statistical analyses were reported with respect to a type-1 error rate of a = 0.05.
Real-time quantitative PCR
Adult slit3 wild type and slit3sa1569 homozygous mutant fish, generated from a slit3sa1569/+ heterozy-
gous in cross, were bred to generate homozygous wild type, heterozygous mutant and homozygous
mutant larvae. Embryos were carefully staged at 1, 24 and 48 hr and at five day post fertilisation to
ensure, based on morphological criteria, there were no differences in development between groups.
mRNA from 3 samples of five-day-old embryos (n = 10 pooled embryos per sample) for each geno-
type was isolated using the phenol-chloroform method. cDNA was generated using the ProtoScript
II First Strand cDNA Synthesis Kit (NEB (UK Ltd.), Hitchen, UK). Relative qPCR assays were per-
formed using the LightCycler 480 qPCR system from Roche Diagnostics, Ltd. with all reactions car-
ried out in triplicates. Reference genes for all the qPCR analyses were b-actin, ef1a and rpl13a
based on previous studies (Parker et al., 2016; Tang et al., 2007; Collier and Echevarria, 2013).
Accession numbers and primer sequences for the genes can be found in Supplementary file 1B.
Relative mRNA expression in qPCR was calculated against reference gene cycle-threshold (Ct)
values, and then subjected to one-way ANOVA. To account for multiple testing a Bonferroni correc-
tion was applied, and significance was declared at a threshold of 0.001.
Human cohorts
In London human subjects were recruited from three clinical groups: patients with chronic obstruc-
tive pulmonary disease (COPD) (Cohort 1; n = 272); patients with asthma (Cohort 2; n = 293); and
residents and carers in sheltered accommodation, with neither condition (Cohort 3; n = 298). The
methods used for recruitment and definition of phenotypes are reported elsewhere
(Martineau et al., 2015a; Martineau et al., 2015b; Martineau et al., 2015c). The studies were
approved by East London and The City Research Ethics Committee 1 (09/H0703/67, 09/H0703/76
and 09/H0703/112). Written informed consent was obtained from all participants.
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Details of the Finnish twin cohort are reported elsewhere (Loukola et al., 2014; Loukola et al.,
2008; Broms et al., 2012). In brief, twin pairs concordant for moderate to heavy smoking were iden-
tified from the population-based Finnish Twin Cohort survey responders. The twin pairs and their
siblings were invited to a computer-assisted, telephone-based, structured, psychiatric interview
(SSAGA) (Loukola et al., 2014), to yield detailed information on smoking behaviour and nicotine
dependence as defined by Fagerstro¨m Test for Nicotine Dependence (FTND) and DSM-IV diagno-
ses. Human phenotypes to be investigated in relation to zebrafish nicotine seeking behaviour were
determined by consensus a priori.
Sample characteristics of the human cohorts can be found in Supplementary file 1C.
Phenotype definitions for the London cohorts
Amount smoked was defined as the average number of cigarettes smoked per day (CPD) for each
participant. Participants met criteria for smoking cessation if they reported being ‘ever smokers’ and
reported not smoking currently. The percentage of current smokers in the cohort was 42%, 7% and
18% for ViDiCO, ViDiAs and ViDiFLU, respectively.
Phenotype definition for the Finnish twin cohort study
Definitions of the phenotypes were adapted from Broms et al. (2012).
Amount smoked
Cigarettes per day (CPD) constitutes of eight categories: 1–2, 3–5, 6–10, 11–15, 16–19, 20–25, 26–
39,40 CPD. In the statistical analyses of the CPD variables, original categorical observations were
replaced with class means of CPD (1.5, 3.5, 8, 13, 17.5, 22.5, 32.5, and 45 cigarettes per day, respec-
tively). Regression coefficients can therefore be interpreted as the average change in number of cig-
arettes smoked per day when the number of minor allele is increased by one.
. CPD: Number of cigarettes smoked per day during month of heaviest smoking. Values ranged
from one to >40 with mean = 19.8 cigarettes per day.
. Maximum CPD: Maximum number of cigarettes ever smoked during one day (24 hr period).
Values ranged from 2 to 98 with mean = 30 cigarettes per day.
Smoking initiation
. Age (years) when started to smoke weekly (“How old were you when you first smoked a ciga-
rette at least once a week for at least two months in a row?”). Values ranged from 6 to 54,
mean = 17.3 years.
. Sensation felt after smoking the first cigarette or first puffs. Sensation measured as: While
smoking your very first cigarettes, did you 1. like the taste or smell of the cigarette, 2. cough,
3. feel dizzy or light-headed, 4. feel more relaxed, 5. get a headache, 6. feel a pleasurable rush
or buzz, 7. feel your heart racing, 8. feel nauseated, like vomiting, 9. feel your muscles tremble
or become jittery, 10. feel burning in your throat. Sum score of 10 questions (items #1, #4, and
#6 were reverse-scored before summation): 0 points if answered ‘No’, 1 = ‘A little bit’,
2=”Some’, 3=‘Quite a bit’, 4=”A great deal’. Cronbach’s alpha = 0.70. Values ranged from 3.6
to 15.8. Mean = 10.2.
Nicotine dependence
. DSM-IV ND diagnosis: Nicotine dependence by DSM-IV diagnosis (3 symptoms out of 7
occurring within a year). Prevalence = 53.5%.
. DSM-IV ND symptoms: Number of DSM-IV ND symptoms from 0 to 7. Mean = 3
. FTND (4): Nicotine dependent if 4 out of 10 points in Fagerstro¨m Test for Nicotine Depen-
dence. Prevalence = 50.4%
. FTND score: Fagerstro¨m Test for Nicotine Dependence score: 0 to 10 points. Mean = 3.7.
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FTND time to first cigarette (TTF)
Time to first cigarette in the morning (one item of the FTND scale). Five categories: 0–5 min, 6–15
min, 16–30 min, 31–60 min, >60 min. Categorization differs from original four categories (Xu et al.,
2015), i.e., 6–30 min is split into 6–15 min and 16–30 min. In our data set 46% of smokers belong to
the group of 6–30 min, and from the smoking behaviour point of view there is a significant difference
whether one smokes the first cigarette within 6 min or 30 min from waking up. In this data set 22%
of smokers belong to the 6–15 min and 24% to the 16–30 min group. Values ranged from 1 to 5
with a mean = 3.1.
Human genotyping
For the London cohorts, DNA from participants was extracted from whole blood using the salting-
out method (Miller et al., 1988) and normalized to 5 ng/mL. 10 ng DNA was used as template for 2
mL TaqMan assays (Applied Biosystems, Foster City, CA, USA) performed on the ABI 7900HT plat-
form in 384-well format and analysed with Autocaller software. Pre-developed assays were used to
type all SNPs. See Supplementary file 1 Table 4 for primer and reporter sequences. Typing for two
SNP (rs6127118 and rs11574010) failed. For the Finnish cohort, DNA was extracted from whole
blood and genotyping was performed at the Wellcome Trust Sanger Institute (Hinxton, UK) on the
Human670-QuadCustom Illumina BeadChip (Illumina, Inc, San Diego, CA, USA), as previously
described (Loukola et al., 2014; Loukola et al., 2008; Broms et al., 2012). Genotyping and imputa-
tion for the Finnish cohort at the Wellcome Trust Sanger Centre have been described previously
(Loukola et al., 2015).
Human association analyses
We attempted to replicate the zebrafish findings initially in a cohort from London using a narrow set
of SNPs in SLIT3. We then used the same set of SNPS to evaluate effects on more detailed smoking
phenotypes in a Finnish twin cohort.
London cohort association analysis was performed using PLINK v1.07 (Purcell et al., 2007). SLIT3
SNPs that had been previously associated with disease phenotype were identified and the 20 with
low linkage disequilibrium score selected for analysis. Of twenty SLIT3 SNPs, one departed from
Hardy-Weinberg equilibrium (rs13183458) and was excluded. Linear regression was performed on
average number of cigarettes smoked per day, controlling for age, sex and cohort. Since physiologi-
cal and genetic mechanisms may be different in heavy (more dependent) and light (less dependent)
smokers we repeated on heavy smokers (20 cigarettes per day) and light smokers (<20 cigarettes
per day). Smoking cessation (current vs ever smokers) was analysed using logistic regression control-
ling for age, sex and cohort. All analyses were performed under the additive genetic model and mul-
tiple testing was taken into account using the Benjamini-Hochberg adjustment. Only individuals from
European ancestry were included in analyses.
Association analyses for the Finnish Twin Cohort were performed using GEMMA v0.94 (Zhou and
Stephens, 2012) with linear mixed model against the allelic dosages controlling for age and sex.
Sample relatedness and population stratification were taken into account by using genetic related-
ness matrix as random effect of the model.
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